Released : March 01, 2019 07:00 RNS Number : 5188R MaxCyte, Inc. 01 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company Gaithersburg, Maryland - 01 March 2019: MaxCyte (LSE: MXCT, MXCS),
Released : February 26, 2019 17:32 RNS Number : 1971R MaxCyte, Inc. 26 February 2019 THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR
Released : February 05, 2019 16:32 RNS Number : 1641P MaxCyte, Inc. 05 February 2019 THIS ANNOUNCEMENT IS RESTRUCTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH
Released : March 05, 2019 07:00 RNS Number : 8081R MaxCyte, Inc. 05 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 05 March 2019 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company , announces that on 04
Released : February 05, 2019 07:00 RNS Number : 0847P MaxCyte, Inc. 05 February 2019 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION
Released : January 15, 2019 07:00 RNS Number : 0746N MaxCyte, Inc. 15 January 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Strong CARMA ™ and financial progress: 19% revenue growth and EBITDA ahead of expectations Gaithersburg, Maryland - 15 JANUARY 2019: MaxCyte
Gaithersburg, Maryland – December 19, 2018: MaxCyte announced today that Debra K. Bowes , Chief Business Officer, CARMA™ Cell Therapy, and Claudio Dansky Ullmann , MD, Chief Medical Officer, will present on the company’s CARMA platform at two upcoming industry conferences: the Biotech Showcase
Released : December 19, 2018 07:00 RNS Number : 8667K MaxCyte, Inc. 19 December 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Change of Auditor Gaithersburg, Maryland - 19 DECEMBER 2018: MaxCyte (LSE: MXCT), the global cell-based medicines and life sciences company, is pleased to
Released : December 17, 2018 18:06 RNS Number : 7483K MaxCyte, Inc. 17 December 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Issue of equity Maryland, USA , 17 December 2018 - MaxCyte (LSE: MXCT) the global cell-based medicines and technology company, announces the
Gaithersburg, Maryland – November 21, 2018: MaxCyte announced today that Doug Doerfler, Chief Executive Officer, will present a company overview at the Piper Jaffray 30th Annual Healthcare Conference on Wednesday, November 28, 2018, at 1:10 p.m. ET in New York City.
